Long‐term outcome of liver transplant patients with Budd‐Chiari syndrome secondary to myeloproliferative neoplasms

Abstract

Budd-Chiari syndrome patients with and without underlying MPN had similar long-term survival rates after OLT. There was no evidence of enhanced progression of MPN after OLT secondary to immunosuppressive therapy. However, major haemorrhage and recurrent thrombosis contributed to morbidity and mortality after OLT in those patients.